SignalCorporate
Clinical trial saves man initially given weeks to live: "Not done yet"
Clinical trial success story signals positive medical research outcome.
Context
What happened: Ryan Goepel, diagnosed with adverse-risk acute myeloid leukemia, entered remission after joining a clinical trial testing two medications typically given to older AML patients on younger patients.
Key numbers: 25 of 36 trial patients saw their cancer shrink or disappear during a 28-day course, with 19 entering complete remission.
Why it matters: The trial results, published in Haematologica, are generating questions about whether the decades-long standard approach to treating these patients should change, according to Dr. Mihir A. Shukla.
What changed
Ryan Goepel, diagnosed with adverse-risk acute myeloid leukemia, entered remission after joining a clinical trial testing two medications typically given to older AML patients on younger patients.
Why it matters
The trial results, published in Haematologica, are generating questions about whether the decades-long standard approach to treating these patients should change, according to Dr. Mihir A. Shukla.